Andere talen Arch Therapeutics, Inc.

Aandelen

ARTH

US03939W2089

Beurs gesloten - OTC Markets Andere beurzen 16:46:00 05-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,99 ^USD	+3,12%		+15,65%	-86,33%

09/05	Arch Therapeutics, Inc. Rapporteert winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 31 maart 2024	CI
06/05	Arch Therapeutics presenteert AC5® Advanced Wound System op de voorjaarsbijeenkomst van 2024 van het Symposium on Advanced Wound Care (SAWC Spring)	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Arch Therapeutics, Inc. announced that it has received $5.058 million in funding from Drake Partners, LLC, Oasis Capital, LLC	30/06
Arch Therapeutics, Inc. announced that it has received $0.15 million in funding	12/06
Arch Therapeutics, Inc. announced that it has received $1.85 million in funding	15/05
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	09/05
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	06/05
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	06/05
Arch Therapeutics : New Financial Obligation - Form 8-K	03/04
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	20/02
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	15/02
Arch Therapeutics : New Financial Obligation - Form 8-K	15/12
Arch Therapeutics Provides Year End Operational Update	09/11
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	02/11
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	02/11
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System	13-09-23
Arch Therapeutics Provides AC5® Commercialization Update	13-09-23
Arch Therapeutics Completes Financing as Bridge to Uplisting	08-09-23
Arch Therapeutics, Inc. announced that it has received $2.560063 million in funding	31-08-23
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	11-08-23
Arch Therapeutics, Inc. announced that it expects to receive $1.850001 million in funding	07-07-23
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arch Therapeutics, Inc.

Aandelen

ARTH

US03939W2089

Andere talen

Filters